1. Q-TER Space Project Milan, 25 th November 2009 Scharper High Solutions a spin-off of Scharper SpA

2. Company presentation Scharper SpA Confidential Group of Pharmaceutical companies, Group of Pharmaceutical companies, Privately owned, Privately owned, European based, European based, Successfully operating in Italy for over 14 years, Successfully operating in Italy for over 14 years, Track record for pioneering the nutraceutical/medical food market in Italy Track record for pioneering the nutraceutical/medical food market in Italy 2008 ValuesDrugs65% Non-Drugs35%

3. Q-TER ® Space Project Current Challenges Confidential Several unmet medical needs caused by free radicals of oxygens (ROS) or mithocondrial disfunctions already exist (both in space and ground medicine) Most of them could be treated by antioxidant agents/metabolism enhancer specific treatments Natural antioxidants need to be dissolved in water before intake have often poor solubility and scarse bioavailability reduced effectiveness

4. Q - TER ® Project description The solution : Q-TER ® Terclatration CoQ 10 Q-TER ® (*) multicomposite has proven to be about 200 times more soluble and to retain its antioxidant capacity more than 5 times with respect to native CoQ 10. potent lipophilic antioxidant involved in mitochondrial oxidative metabolism insoluble substance (poor bioavailability & stability problems) dry co-grinding method which: allows the attainment of ternary compositions (active substance, a hydrophilic or hydrophobic carrier, a co- grinding agent) confers solubility and dissolution speed desired Confidential

5. Project description Q-TER ® - IP position Terclatration process has been covered by the granted patent WO03097012 claiming the process of dry co-grinding of a ternary mixture comprising: an active substance hydrophilic or hydrophobic carrier co-grinding auxiliary substance required for activating the incorporation of the active substance in the carrier. Scharper owns the worldwide exclusive rights of commercial and scientific exploitation of Q-TER® up to patent expiry date Confidential

6. Project description The solution: Proof of concept Confidential Proof of concept data already available for mitocondria related diseases: Disease A Disease B Disease C Disease D Confidential info available (NDA required) (*) free radicals

7. Project description Potential market (*) Confidential Expected number of patients (USA + EU) (*) epidemiological studies trend Disease ADisease BDisease CDisease D 20131.172.62111.361.20313.386.33313.049.697 20231.321.18312.175.61317.945.29314.702.986

8. Q-TER ® Space Project Competition Confidential Current solutions do not meet patients’ needs as they: are not effective are expensive and have heavy side-effects have a limited mechanism of action

9. Q-TER ® space project: Develop new drug deliveries patches sublingual tabs Gather new proof of concept data Project description Q-TER ® : current & future applications Q - TER ® already formulated in Confidential Mental & physical fatigue Powder in sachet Dizziness & tinnitus Powder in sachet dissolved in water after shaking before the intake Medical needs: Disease A Disease B Disease C Disease D

10. Q-TER ® Space Project The investment opportunity Confidential solid scientific evidence proven business model skills to product development already available within organization product development (nutraceuticals and medical foods vs drugs) lower investments and development risks shorter time to market finalize spin-off SHS operations among Scharper activities

11. Project description Timeline Confidential Project start Y1 Y2 Y3 Y4 Product (3) (disease C) Product 4 (disease D) Technology development phase Y5 Proof of concept studies (*) Disease A/B Disease C Disease D Product (2) (disease B) Product (1) (disease A) Go/no Go decision (*) Pharmacokinetics – Animal studies

12. Project description Financials: Whole sales revenues (€) Confidential

13. Funding & financial Funding requirements and timeline The objective that SHS intend to reach with funding required is to fully explore prototypes of potential nutraceutical products to launch on the market. Timing to invest/spend money raised by funding programme. Confidential Required step by step following go/no Go decision

14. Marco Cartolari, MBA Managing Director mcartolari@scharper.it Marco Castelnovo, MBA New Products & Business Development Manager mcastelnovo@scharper.it Antonella Sblendido Medical Affairs asblendido@scharper.it Management & Contacts Scharper S.p.A Via Milanese 20 20099 – Sesto San Giovanni (MI) Ph: +39 02 2629161 Confidential